- Record: found
- Abstract: found
- Article: not found
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Mark A Socinski
1 ,
Thomas E Stinchcombe ,
Dominic T Moore ,
Scott N Gettinger ,
Roy H Decker ,
W Jeffrey Petty ,
A William Blackstock ,
Garry Schwartz ,
Scott Lankford ,
Amir Khandani ,
David E Morris
Nov 10 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). This phase I/II trial was designed to incorporate these agents with induction and concurrent chemoradiotherapy in stage III NSCLC.